Rosetta Genomics Ltd. has received regulatory approval for their diagnostic test using MicroRNA technology to differentiate between squamous and non-squamous non-small cell lung cancer (NSCLC).
At present, the test is approved for clinical use by the New York State Department of Health Clinical Laboratory Evaluation Program and is expected to become available nationwide at the end of 2008. The diagnostic test utilizes a tumor tissue sample for MicroRNA testing with a sensitivity and specificity of over 90% for identification of squamous cell NSCLC.
FDA - Breast Implants Linked to Development of Anaplastic Lymphoma
Breast implants associated with risk of rare lymphoma cancer